Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by RenovoRx, Inc.
< Previous
1
2
Next >
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
April 27, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
April 14, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
April 11, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
March 30, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
March 30, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
March 08, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
March 02, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
March 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
January 25, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
January 18, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
January 05, 2023
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
December 15, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
November 17, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Reports Third Quarter 2022 Financial Results
November 14, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET
October 21, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
October 04, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
September 28, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
September 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
September 07, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Reports Second Quarter 2022 Financial Results
August 15, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Appoints James Ahlers as Chief Financial Officer
July 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Launches “The RenovoRx Story” Video Series
July 13, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022
June 09, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022
June 02, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform’s Potential Utility for the Treatment of Bile Duct Cancer
May 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
May 18, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Reports First Quarter 2022 Financial Results
May 16, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride Event to End Pancreatic Cancer
April 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Full Year 2021 Financial Results
March 30, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
February 22, 2022
From
RenovoRx, Inc.
Via
Business Wire
Tickers
RNXT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.